MENODYS and Univalor announce the signature of an exclusive agreement to develop and commercialize an innovative technology for the objective assessment of tinnitus

Longueuil, Quebec, Canada – MENODYS and Univalor, the University of Montreal’s office of technology transfer, have agreed to the terms of an exclusive license option to a medical technology developed by Pr Sylvie Hébert, of the School of Speech Pathology and Audiology of the University of Montreal.

This technology offers a new approach for the objective assessment of the frequency and amplitude of tinnitus. Tinnitus is an important health issue in audiology affecting more than 360 000 Canadians and 30 millions Americans.

The agreement is the second to take place between Univalor and MENODYS will accelerate the development and marketing of a technology targeting a specific need. “We look forward to work again with MENODYS who proved to be a worthy partner in the commercialization of innovations in the sector of medical technology,” said Clermont Beaulieu, manager in Life Sciences at Univalor.

“ We are excited about this new agreement with Univalor which confirms our business model of accelerating the transfer and international commercialization of innovations in the medical device sector” said Richard Côté, Executive vice president at MENODYS.